The role of sumoylation in neurodegenerative diseases

SUMO Regulation of Cellular Processes

Volumn , Issue , 2009, Pages 233-251

  Anderson, Dina B ^a   Cimarosti, Helena ^a   Henley, Jeremy M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alzheimer's disease; Drug targets; Ischemia; Neuronal intranuclear inclusion disease; Parkinson's disease; Polyglutamine diseases

Indexed keywords

EID: 84901179728     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-2649-1_14     Document Type: Chapter

References (85)

1. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., Trojanowski, J. Q. and Iwatsubo, T., 1998, Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinsons disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884.
2. Bae, S. H., Jeong, J. W., Park, J. A., Kim, S. H., Bae, M. K., Choi, S. J. and Kim, K. W., 2004, Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem. Biophys. Res. Commun. 324, 394-400.
3. Ballatore, C., Lee, V. M. and Trojanowski, J. Q., 2007, Tau-mediated neurodegeneration in Alzheimers disease and related disorders. Nat. Rev. Neurosci. 8, 663-672.
4. Capili, A. D. and Lima, C. D., 2007, Structure and analysis of a complex between SUMO and Ubc9 illustrates features of a conserved E2-Ubl interaction. J. Mol. Biol. 369, 608-618.
5. Carbia-Nagashima, A., Gerez, J., Perez-Castro, C., Paez-Pereda, M., Silberstein, S., Stalla, G. K., Holsboer, F. and Arzt, E., 2007, RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131, 309-323.
6. Chan, H. Y., Warrick, J. M., Andriola, I., Merry, D. and Bonini, N. M., 2002, Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum. Mol. Genet. 11, 2895-2904.
7. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M. and Sudhof, T. C., 2005, Alphasynuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123, 383-396.
8. Cheng, J., Kang, X., Zhang, S. and Yeh, E. T., 2007, SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131, 584-595.
9. Ciechanover, A. and Brundin, P., 2003, The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40, 427-446.
10. Cimarosti, H. and Henley, J. M., 2008, Investigating the mechanisms underlying neuronal death in ischaemia using in vitro oxygen-glucose deprivation: potential involvement of protein SUMOylation. The Neuroscientist 14, 626-636.
11. Cimarosti, H., Lindberg, C., Bomholt, S. F., Ronn, L. C. and Henley, J. M., 2008, Increased protein SUMOylation following focal cerebral ischemia. Neuropharmacology 54, 280-289.
12. David, G., Neptune,M. A. and DePinho, R. A., 2002, SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J. Biol. Chem. 277, 23658-23663.
13. Dorval, V. and Fraser, P. E., 2006, Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J. Biol. Chem. 281, 9919-9924.
14. Dorval, V. and Fraser, P. E., 2007, SUMO on the road to neurodegeneration. Biochim. Biophys. Acta 1773, 694-706.
15. Dorval, V., Mazzella,M. J., Mathews, P. M., Hay, R. T. and Fraser, P. E., 2007, Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins. Biochem. J. 404, 309-316.
16. Fei, E., Jia, N., Yan, M., Zing, Z., Sun, Z., Wang, H., Zhang, T., Ma, X., Ding, H., Yao, X., Shi, Y. and Wang, G., 2006, SUMO-1 modification increases human SOD1 stability and aggregation. Biochem. Biophys. Res. Commun. 347, 406-412.
17. Gatchel, J. R. and Zoghbi, H. Y., 2005, Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet. 6, 743-755.
18. Gil, J. M. and Rego, A. C., 2008, Mechanisms of neurodegeneration in Huntingtons disease. Eur. J. Neurosci. 27, 2803-2820.
19. Gocke, C. B., Yu, H. and Kang, J., 2005, Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates. J. Biol. Chem. 280, 5004-5012.
20. Guedat, P. and Colland, F., 2007, Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem. 8, S14.
21. Heun, P., 2007, SUMOrganization of the nucleus. Curr. Opin. Cell Biol. 19, 350-355.
22. Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G., Masucci, M., Pramanik, A. and Selivanova, G., 2004, Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321-1328.
23. Johnson, F. and Giulivi, C., 2005, Superoxide dismutases and their impact upon human health. Mol. Aspects Med. 26, 340-352.
24. Kerscher, O., 2007, SUMO junction-whats your function? New insights through SUMOinteracting motifs. EMBO Rep. 8, 550-555.
25. Lee, Y. J. and Hallenbeck, J. M., 2006, Insights into cytoprotection from ground squirrel hibernation, a natural model of tolerance to profound brain oligaemia. Biochem. Soc. Trans. 34, 1295-1298.
26. Lee, Y. J., Miyake, S., Wakita, H., McMullen, D. C., Azuma, Y., Auh, S. and Hallenbeck, J. M., 2007, Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells. J. Cereb. Blood Flow Metab. 27, 950-962.
27. Li, Y., Wang, H., Wang, S., Quon, D., Liu, Y. W. and Cordell, B., 2003, Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc. Natl. Acad. Sci. U. S. A. 100, 259-264.
28. Lieberman, A. P., Robitaille, Y., Trojanowski, J. Q., Dickson, D. W. and Fischbeck, K. H., 1998, Polyglutamine-containing aggregates in neuronal intranuclear inclusion disease. Lancet 351, 884.
29. Lieberman, A. P., Trojanowski, J. Q., Leonard, D. G., Chen, K. L., Barnett, J. L., Leverenz, J. B., Bird, T. D., Robitaille, Y., Malandrini, A. and Fischbeck, K. H., 1999, Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease. Ann. Neurol. 46, 271-273.
30. Liu, B. and Shuai, K., 2008, Targeting the PIAS1 SUMO ligase pathway to control inflammation. Trends Pharmacol. Sci. 29, 505-509.
31. Lois, L. M. and Lima, C. D., 2005, Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 24, 439-451.
32. Martin, S., Nishimune, A., Mellor, J. R. and Henley, J. M., 2007a, SUMOylation regulates kainatereceptor-mediated synaptic transmission. Nature 447, 321-325.
33. Martin, S.,Wilkinson, K. A., Nishimune, A. and Henley, J. M., 2007b, Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nat. Rev. Neurosci. 8, 948-959.
34. McCoy, M. K. and Tansey, M. G., 2008, TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 5, 45.
35. McFadden, K., Hamilton, R. L., Insalaco, S. J., Lavine, L., Al-Mateen,M.,Wang, G. andWiley, C. A., 2005, Neuronal intranuclear inclusion disease without polyglutamine inclusions in a child. J. Neuropathol. Exp. Neurol. 64, 545-552.
36. Michels, G. and Hoppe, U. C., 2008, Rapid actions of androgens. Front. Neuroendocrinol. 29, 182-198.
37. Moore, D. J., Zhang, L., Dawson, T. M. and Dawson, V. L., 2003, A missense mutation (L166P) in DJ-1, linked to familial Parkinsons disease, confers reduced protein stability and impairs homo-oligomerization. J. Neurochem. 87, 1558-1567.
38. Mukhopadhyay, D. and Dasso, M., 2007, Modification in reverse: the SUMO proteases. Trends Biochem. Sci. 32, 286-295.
39. Nalepa, G., Rolfe, M. and Harper, J. W., 2006, Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5, 596-613.
40. Navascues, J., Bengoechea, R., Tapia, O., Casafont, I., Berciano, M. T. and Lafarga, M., 2008, SUMO-1 transiently localizes to Cajal bodies in mammalian neurons. J. Struct. Biol. 163, 137-146.
41. Olzmann, J. A., Brown, K., Wilkinson, K. D., Rees, H. D., Huai, Q., Ke, H., Levey, A. I., Li, L. and Chin, L. S., 2004, Familial Parkinsons disease-associated L166P mutation disrupts DJ-1 protein folding and function. J. Biol. Chem. 279, 8506-8515.
42. Poukka, H., Karvonen, U., Janne, O. A. and Palvimo, J. J., 2000, Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. U. S. A. 97, 14145-14150.
43. Pountney, D. L., Chegini, F., Shen, X., Blumbergs, P. C. and Gai, W. P., 2005, SUMO-1 marks subdomains within glial cytoplasmic inclusions of multiple system atrophy. Neurosci. Lett. 381, 74-79.
44. Pountney, D. L., Huang, Y., Burns, R. J., Haan, E., Thompson, P. D., Blumbergs, P. C. and Gai, W. P., 2003, SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp. Neurol. 184, 436-446.
45. Pountney, D. L., Raftery, M. J., Chegini, F., Blumbergs, P. C. and Gai, W. P., 2008, NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1- immunocapture. Acta Neuropathol. 116, 603-614.
46. Ren, R., 2005, Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172-183.
47. Reverter, D. and Lima, C. D., 2005, Insights into E3 ligase activity revealed by a SUMORanGAP1-Ubc9-Nup358 complex. Nature 435, 687-692.
48. Reverter, D. and Lima, C. D., 2006, Structural basis for SENP2 protease interactions with SUMO precursors and conjugated substrates. Nat. Struct. Mol. Biol. 13, 1060-1068.
49. Riley, B. E., Zoghbi, H. Y. and Orr, H. T., 2005, SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J. Biol. Chem. 280, 21942-21948.
50. Ross, C. A. and Poirier,M. A., 2004, Protein aggregation and neurodegenerative disease. Nat. Med. 10, S10-S17.
51. Saitoh, H. and Hinchey, J., 2000, Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275, 6252-6258.
52. Sampson, D. A.,Wang, M. and Matunis, M. J., 2001, The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276, 21664-21669.
53. Schilling, G.,Wood, J. D., Duan, K., Slunt, H. H., Gonzales, V., Yamada,M., Cooper, J. K.,Margolis, R. L., Jenkins, N. A., Copeland, N. G., Takahashi, H., Tsuji, S., Price, D. L., Borchelt, D. R. and Ross, C. A., 1999, Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 24, 275-286.
54. Seeler, J. S. and Dejean, A., 2003, Nuclear and unclear functions of SUMO. Nat. Rev. Cell Biol. 4, 690-699.
55. Shao, R., Zhang, F. P., Tian, F., Anders Friberg, P., Wang, X., Sjoland, H. and Billig, H., 2004, Increase of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1alpha in adult mouse brain and heart in vivo. FEBS Lett. 569, 293-300.
56. Shen, L., Tatham, M. H., Dong, C., Zagorska, A., Naismith, J. H. and Hay, R. T., 2006, SUMO protease SENP1 induces isomerization of the scissile peptide bond. Nat. Struct. Mol. Biol. 13, 1069-1077.
57. Shinbo, Y., Niki, T., Taira, T., Ooe, H., Takahashi-Niki, K., Maita, C., Seino, C., Iguchi-Ariga, S. M. and Ariga, H., 2006, Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ. 13, 96-108.
58. Spillantini, M. G., Schmidt,M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R. and Goedert,M., 1997, Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
59. Sramko, M., Markus, J., Kabat, J., Wolff, L. and Bies, J., 2006, Stress-induced inactivation of the c-Myb transcription factor through conjugation of SUMO-2/3 proteins. J. Biol. Chem. 281, 40065-40075.
60. Steffan, J. S., Agrawal, N., Pallos, J., Rockabrand, E., Trotman, L. C., Slepko, N., Illes, K., Lukacsovich, T., Zhu, Y. Z., Cattaneo, E., Pandolfi, P. P., Thompson, L. M. and Marsh, J. L., 2004, SUMO modification of Huntingtin and Huntington disease pathology. Science 304, 100-104.
61. Taira, T., Saito, Y., Niki, T., Iguchi-Ariga, S. M., Takahashi, K. and Ariga, H., 2004, DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5, 213-218.
62. Takahashi-Fujigasaki, J., Arai, K., Funata, N. and Fujigasaki, H., 2006, SUMOylation substrates in neuronal intranuclear inclusion disease. Neuropathol. Appl. Neurobiol. 32, 92-100.
63. Takahashi, K., Ishida, M., Komano, H. and Takahashi, H., 2008, SUMO-1 immunoreactivity colocalizes with phospho-Tau in APP transgenic mice but not in mutant Tau transgenic mice. Neurosci. Lett. 441, 90-93.
64. Takahashi, K., Taira, T., Niki, T., Seino, C., Iguchi-Ariga, S. M. and Ariga, H., 2001, DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J. Biol. Chem. 276, 37556-37563.
65. Tan, E. K. and Skipper, L. M., 2007, Pathogenic mutations in Parkinson disease. Hum Mutat. 28, 641-653.
66. Tempe, D., Piechaczyk, M. and Bossis, G., 2008, SUMO under stress. Biochem. Soc. Trans. 36, 874-878.
67. Terashima, T., Kawai, H., Fujitani, M., Maeda, K. and Yasuda, H., 2002, SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death. Neuroreport 13, 2359-2364.
68. Tiraboschi, P., Hansen, L. A., Thal, L. J. and Corey-Bloom, J., 2004, The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1989.
69. Ueda, H., Goto, J., Hashida, H., Lin, X., Oyanagi, K., Kawano, H., Zoghbi, H. Y., Kanazawa, I., and Okazawa, H, 2002, Enhanced SUMOyalation in polyglutamine diseases. Biochem Biophys Res Commun. 293, 307-13.
70. Um, J. W. and Chung, K. C., 2006, Functional modulation of parkin through physical interaction with SUMO-1. J. Neurosci. Res. 84, 1543-1554.
71. Um, J. W., Min, D. S., Rhim, H., Kim, J., Paik, S. R. and Chung, K. C., 2006, Parkin ubiquitinates and promotes the degradation of RanBP2. J. Biol. Chem. 281, 3595-3603.
72. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N. and Liu, E. A., 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848.
73. Wakabayashi, K., Tanji, K., Mori, F. and Takahashi, H., 2007, The Lewy body in Parkinson disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27, 494-506.
74. Wang, L., Charroux, B., Kerridge, S. and Tsai, C. C., 2008, Atrophin recruits HDAC1/2 and G9a to modify histone H3K9 and to determine cell fates. EMBO Rep. 9, 555-62.
75. Wolfe, M. S., 2006, The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochem. 45, 7931-7939.
76. Wuerzberger-Davis, S. M., Nakamura, Y., Seufzer, B. J. and Miyamoto, S., 2007, NF-kappaB activation by combinations of NEMO SUMOylation and ATMactivation stresses in the absence of DNA damage. Oncogene 26, 641-651.
77. Yang,W., Sheng, H., Homi, H. M.,Warner, D. S. and Paschen,W., 2008a, Cerebral ischemia/stroke and small ubiquitin-like modifier (SUMO) conjugation-a new target for therapeutic intervention? J. Neurochem. 106, 989-999.
78. Yang, W., Sheng, H., Warner, D. S. and Paschen, W., 2008b, Transient focal cerebral ischemia induces a dramatic activation of small ubiquitin-like modifier conjugation. J. Cereb. Blood Flow Metab. 28, 892-896.
79. Yang, W., Sheng, H., Warner, D. S. and Paschen, W., 2008c, Transient global cerebral ischemia induces a massive increase in protein sumoylation. J. Cereb. Blood Flow Metab. 28, 269-279.
80. Yazawa, I., Nukina, N., Hashida, H., Goto, J., Yamada, M. and Kanazawa, I., 1995, Abnormal gene product identified in hereditary dentatorubral- pallidoluysian atrophy (DRPLA) brain. Nat. Genet. 10, 99-103.
81. Yunus, A. A. and Lima, C. D., 2006, Lysine activation and functional analysis of E2-mediated conjugation in the SUMO pathway. Nat. Struct. Mol. Biol. 13, 491-499.
82. Zhang, J., Goodson, M. L., Hong, Y. and Sarge, K. D., 2008, MEL-18 interacts with HSF2 and the SUMO E2 UBC9 to inhibit HSF2 sumoylation. J. Biol. Chem. 283, 7464-7469.
83. Zhang, Y. Q. and Sarge, K. D., 2008, Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels. Biochem. Biophys. Res. Commun. 374, 673-678.
84. Zhao, X., Sternsdorf, T., Bolger, T. A., Evans, R. M. and Yao, T. P., 2005, Regulation of MEF2 by histone deacetylase 4-and SIRT1 deacetylase-mediated lysine modifications. Mol. Cell. Biol. 25, 8456-8464.
85. Zoghbi, H. Y. and Orr, H. T., 2000, Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247.